X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
VS-6766 (avutometinib) is a RAF/MEK clamp that induces inactive complexes of MEK with ARAF, BRAF and CRAF potentially creating a more complete and durable anti-tumor response through maximal RAS pathway inhibition.
Lead Product(s): VS-6766,Defactinib
Therapeutic Area: Oncology Product Name: VS-6766
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
VS-6766 (avutometinib) in combination with Lumakras (sotorasib) is being evaluated in phase 1/2 clinical studies for the treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC).
Lead Product(s): VS-6766,Sotorasib
Therapeutic Area: Oncology Product Name: VS-6766
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2024
Details:
VS-6766 (avutometinib) is a RAF/MEK clamp that induces inactive complexes of MEK with ARAF, BRAF and CRAF potentially creating a more complete and durable anti-tumor response through maximal RAS pathway inhibition.
Lead Product(s): VS-6766,Defactinib
Therapeutic Area: Oncology Product Name: VS-6766
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2023
Details:
VS-6766 (avutometinib) is a RAF/MEK clamp that induces inactive complexes of MEK with ARAF, BRAF and CRAF potentially creating a more complete and durable anti-tumor response Low-Grade Serous Ovarian Cancer through maximal RAS pathway inhibition.
Lead Product(s): VS-6766,Defactinib
Therapeutic Area: Oncology Product Name: VS-6766
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2023
Details:
Verastem Oncology intends to use the net proceeds for potential launch of VS-6766 (avutometinib), a small molecule RAF/MEK clamp, and defactinib in low-grade serous ovarian cancer.
Lead Product(s): VS-6766,Defactinib
Therapeutic Area: Oncology Product Name: VS-6766
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: RBC Capital Markets
Deal Size: $85.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 16, 2023
Details:
VS-6766 (avutometinib) is a RAF/MEK clamp that induces inactive complexes of MEK with ARAF, BRAF and CRAF potentially creating a more complete and durable anti-tumor response through maximal RAS pathway inhibition.
Lead Product(s): VS-6766,Defactinib
Therapeutic Area: Oncology Product Name: VS-6766
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
VS-6766 is a RAF/MEK clamp that induces inactive complexes of MEK with ARAF, BRAF and CRAF potentially creating a more complete and durable anti-tumor response through maximal RAS pathway inhibition.
Lead Product(s): VS-6766,Defactinib
Therapeutic Area: Oncology Product Name: VS-6766
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Truist Securities
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 24, 2023
Details:
VS-6766 (avutometinib) is a RAF/MEK clamp that induces inactive complexes of MEK with ARAF, BRAF and CRAF potentially creating a more complete and durable anti-tumor response through maximal RAS pathway inhibition.
Lead Product(s): VS-6766,Defactinib
Therapeutic Area: Oncology Product Name: VS-6766
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Details:
VS-6766 is a RAF/MEK clamp that induces inactive complexes of MEK with ARAF, BRAF and CRAF potentially creating a more complete and durable anti-tumor response through maximal RAS pathway inhibition.
Lead Product(s): VS-6766,Defactinib
Therapeutic Area: Oncology Product Name: VS-6766
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2022
Details:
The analysis indicated encouraging efficacy results with confirmed responses by independent review in patients treated with VS-6766 monotherapy and patients treated with VS-6766 in combination with defactinib.
Lead Product(s): VS-6766,Defactinib
Therapeutic Area: Oncology Product Name: VS-6766
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
This clinical collaboration agreement will initiate to evaluate the combination of Mirati's investigational KRASG12C inhibitor adagrasib with Verastem Oncology's investigational RAF/MEK inhibitor VS-6766 in KRASG12C-mutant non-small cell lung cancer (NSCLC).
Lead Product(s): Adagrasib,VS-6766
Therapeutic Area: Oncology Product Name: MRTX849
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Verastem Oncology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 22, 2021
Details:
Verastem has signed collaboration agreement to explore the potential of VS-6766 as a therapy to treat RAS pathway-driven cancers and to evaluate the combination of VS-6766 with Amgen’s KRAS G12C inhibitor LUMAKRAS (sotorasib) in KRAS G12C-mutant non-small cell lung cancer.
Lead Product(s): VS-6766,Sotorasib
Therapeutic Area: Oncology Product Name: VS-6766
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 20, 2021
Details:
The treatment combination comprised VS-6766 and defactinib, which can potentially hinder signals ovarian cancer to grow. VS-6766 is a dual RAF/MEK inhibitor of Verastem Oncology while defactinib is a FAK inhibitor.
Lead Product(s): VS-6766,Defactinib
Therapeutic Area: Oncology Product Name: VS-6766
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2021
Details:
The combination of VS-6766 with defactinib is being evaluated in the ongoing investigator-initiated Phase 1/2 FRAME trial. VS-6766 is a novel dual inhibitor of the RAF/MEK signaling pathway. VS-6766 confers vertical inhibition of the RAS pathway in a single drug.
Lead Product(s): VS-6766,Defactinib
Therapeutic Area: Oncology Product Name: VS-6766
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2021
Details:
Verastem Oncology is evaluating VS-6766 in combination with agents targeting other nodes in the RAS pathway as well as with agents targeting parallel pathways to address multiple cancer indications and mutations.
Lead Product(s): VS-6766
Therapeutic Area: Oncology Product Name: VS-6766
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2021
Details:
The RAMP 202 study is a Phase 2, adaptive two-part multicenter trial to evaluate the efficacy and safety of VS-6766 alone and in combination with defactinib in patients with KRAS mutant NSCLC, following treatment with a platinum-based regimen and immune checkpoint inhibitor.
Lead Product(s): VS-6766,Defactinib
Therapeutic Area: Oncology Product Name: VS-6766
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2020
Details:
The Phase 2 study (GOG3052) is an adaptive two-part multicenter, parallel cohort, randomized, open label trial to evaluate the efficacy and safety of VS-6766 alone and in combination with defactinib in patients with recurrent LGSOC.
Lead Product(s): VS-6766,Defactinib
Therapeutic Area: Oncology Product Name: VS-6766
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2020
Details:
Preliminary data on VS-6766 and defactinib combination continues to show encouraging response rates, durability and a favorable safety profile in KRAS mutant low-grade serous ovarian cancer in investigator-initiated trial.
Lead Product(s): VS-6766,Defactinib
Therapeutic Area: Oncology Product Name: VS-6766
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2020
Details:
Company announced positive results from a study that provides preclinical proof-of-concept for combining VS-6766, its RAF/MEK inhibitor, with defactinib, its focal adhesion kinase (FAK) inhibitor, for the treatment of metastatic uveal melanoma (UM).
Lead Product(s): VS-6766,Defactinib
Therapeutic Area: Oncology Product Name: VS-6766
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
Combination of VS-6766 and Defactinib demonstrates 67% overall response rate in kras mutant low-grade serous ovarian cancer in phase 1 trial.
Lead Product(s): VS-6766,Defactinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020
Details:
Company will discuss the clinical data from the ongoing investigator-initiated study investigating VS-6766, in combination with defactinib, in patients with KRAS mutant advanced solid tumors.
Lead Product(s): VS-6766,Defactinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2020
Details:
The Company’s primary focus will be on the development of CH5126766 its RAF/MEK inhibitor, in combination with defactinib, for the treatment of KRAS mutant solid tumors.
Lead Product(s): VS-6766,Defactinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2020
Details:
Under the terms of the agreement, Verastem Oncology is responsible for the development and worldwide commercialization of CH5126766.
Lead Product(s): VS-6766,Defactinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Verastem Oncology
Deal Size: Undisclosed Upfront Cash: $3.0 million
Deal Type: Licensing Agreement January 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
